Kristin Bains, MD
Ophthalmology · Birmingham, ALNPI 1386847374
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Glaukos Corporation at 47.2% of the total. 2025 is the largest year on record at $22,631, 3.1 times the $7,309 reported in 2019. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $154.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$19K
- Dompe US, Inc.$7K
- Shire North American Group Inc$7K
- Alcon$3K
- AbbVie$573
- Biotissue Holdings Inc.$531
- plus $2K from 17 others
What the payments were for
- Consulting fees$12,82532%
- Speaking & faculty fees$12,00930%
- Travel & lodging$4,30111%
- Food & beverage$10,83127%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 72 | $18,884 |
| Dompe US, Inc. | 20 | $7,488 |
| Shire North American Group Inc | 17 | $7,157 |
| Alcon | 38 | $2,947 |
| AbbVie(2 entities) | 29 | $573 |
| Biotissue Holdings Inc. | 6 | $531 |
| Sun Pharmaceutical Industries Inc. | 16 | $380 |
| Bristol Myers Squibb | 1 | $300 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $295 |
| Bausch & Lomb Americas Inc. | 11 | $289 |
| Kala Pharmaceuticals, Inc. | 1 | $239 |
| Harrow Eye, LLC | 10 | $236 |
| Oyster Point Pharma, Inc. | 10 | $182 |
| Novartis | 8 | $164 |
| Amgen | 4 | $77 |
| NEW World Medical,inc. | 3 | $64 |
| Omeros Corporation | 1 | $57 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| Ocular Therapeutix, Inc. | 2 | $37 |
| Rxsight Inc | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$7,492
- Oxervate$7,259
- XIIDRA$6,952
- KXL System$3,685
- CE-marked KXLA system$2,785
- Travoprost Intraocular Implant - iDose$1,779
- LenSx$913
- Photrexa Viscous and Photrexa$903
- Clareon$638
- Prokera$325
- AmnioGraft$325
- Clareon PanOptix Pro$260
- INVELTYS$239
- Tecnis IOL$109
- Photrexa$106
How this compares
$40,010 in reported general payments places this provider in the 95th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 31 | $1,181,254 |
| RestasisCyclosporine | 275 | $277,271 |
| XiidraLifitegrast | 118 | $130,448 |
| Cyclosporine | 196 | $128,856 |
| Fluorometholone | 481 | $37,896 |
| Prednisolone Acetate | 668 | $35,350 |
| TyrvayaVarenicline Tartrate | 52 | $33,678 |
| XdemvyLotilaner | 16 | $29,242 |
| Loteprednol Etabonate | 67 | $11,213 |
| ValacyclovirValacyclovir Hcl | 228 | $9,525 |
| MoxifloxacinMoxifloxacin Hcl | 226 | $7,118 |
| LumiganBimatoprost | 13 | $5,472 |
| Pred FortePrednisolone Acetate | 24 | $4,579 |
| Latanoprost | 256 | $4,428 |
| Azelastine Hcl | 118 | $3,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $7,488 | $1,181,25431 claims |
| AbbVieRestasis, Lumigan | $573 | $282,743288 claims |
| Bausch & Lomb Americas Inc.Xiidra | $289 | $130,448118 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $182 | $33,67852 claims |
| AlconSimbrinza | $2,947 | $2,78813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Birmingham
- Lindsay RhodesBirmingham$18K
- James LewisBirmingham$15K
- Marc MichelsonBirmingham$9K
- Jennifer MichelsonBirmingham$8K
- John MasonBirmingham$7K
- Walter ParkerBirmingham$6K
- Priscilla FowlerBirmingham$6K
- Mark BearmanBirmingham$5K
- Michael AlbertBirmingham$5K
- Kathleen GeeBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.